The Patent Finder

Aeterna Zentaris, Inc.

Also on record
Records under this name other than the patents Aeterna Zentaris, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Aeterna Zentaris, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,921,318Application of Initial Doses of LHRH Analogues and Maintenance Doses of LHRH Antagonists for the Treatment of Hormone-Dependent Cancers and Corresponding Pharmaceutical Kits
Held by another company
In force
 · High confidence
In forceHigh confidence
US 10,288,629Method of Assessing Growth Hormone Deficiency in Humans by a Macimorelin Containing Composition
Held by another company
In force
 · High confidence
In forceHigh confidence
US 8,546,435Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
Held by another company
Lapsed on the fee record
Ended Oct 1, 2025 · High confidence
Lapsed on the fee recordEnded Oct 1, 2025High confidence
US 7,887,817Process for preventing protozoal diseases
Term ended
Term ended Dec 22, 2024 · USPTO record
Term endedTerm ended Dec 22, 2024USPTO record
US 8,551,977Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
Term ended
Term ended Jan 31, 2024 · USPTO record
Term endedTerm ended Jan 31, 2024USPTO record
US 8,389,497Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
Term ended
Ended no later than Jul 30, 2023 · USPTO record
Term endedEnded no later than Jul 30, 2023USPTO record
US 8,507,710Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
Lapsed on the fee record
Ended Aug 13, 2021 · USPTO record
Lapsed on the fee recordEnded Aug 13, 2021USPTO record
US 8,470,776Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
Lapsed on the fee record
Ended Jun 25, 2021 · USPTO record
Lapsed on the fee recordEnded Jun 25, 2021USPTO record
US 8,461,178Naphthyridine derivatives and the use thereof as kinase inhibitors
Lapsed on the fee record
Ended Jun 11, 2021 · USPTO record
Lapsed on the fee recordEnded Jun 11, 2021USPTO record
US 8,383,605Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
Lapsed on the fee record
Ended Feb 26, 2021 · USPTO record
Lapsed on the fee recordEnded Feb 26, 2021USPTO record
10 of 45 patents shown.
Pro members see all 45.
Pro members: see all 45 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited